Nanotechnology in the Treatment of Inflammatory Bowel Disease

被引:25
|
作者
Giron, Fanny [1 ]
Pasto, Anna [2 ]
Tasciotti, Ennio [3 ,4 ]
Abraham, Bincy P. [3 ,4 ]
机构
[1] Univ Catolica Honduras, San Pedro Sula, Honduras
[2] Ist Oncol Veneto IRCCS, Padua, Italy
[3] Houston Methodist Hosp, Underwood Ctr Digest Disorders, Houston, TX 77030 USA
[4] Houston Methodist Hosp, Houston Methodist Res Inst, Houston, TX 77030 USA
关键词
inflammatory bowel disease; nanoparticles; leukosomes; drug delivery; treatment; PH-SENSITIVE NANOPARTICLES; VASOACTIVE-INTESTINAL-PEPTIDE; IMMUNE-REGULATING CELLS; COLON-SPECIFIC DELIVERY; TNBS-INDUCED COLITIS; DRUG-DELIVERY; IN-VIVO; 5-AMINOSALICYLIC ACID; ULCERATIVE-COLITIS; TRIPEPTIDE KPV;
D O I
10.1093/ibd/izz205
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Due to the lack of cure for inflammatory bowel disease (IBD) and failure of current medical therapies in many patients with IBD, a need exists in finding novel ways to treat inflammation with a high benefit and the lowest risk possible. With current medical therapies, adverse events or risks of cancer/lymphoma and infections prevent patients-and sometimes providers-in using effective therapies for treatment. Some patients develop systemic side effects that preclude them from continuing a therapy that may have been efficacious, or in other cases, current medical therapies are not adequate to control disease. Nanotechnology is an emerging field where particles, in the size of nanometers, can be used to deliver medications directly to the area of inflammation thus avoiding drug-associated systemic side effects. When using nanoparticles (NPs), only a small amount of the drug is needed, and it can be delivered directly to the inflamed site without exposure to the rest of the body. Here we review conventional and unconventional therapies applied in the treatment of IBD underlying how the introduction of NPs has improved their safety and efficacy.
引用
收藏
页码:1871 / 1880
页数:10
相关论文
共 50 条
  • [31] Biosimilars for the Treatment of Inflammatory Bowel Disease
    Rudrapatna, Vivek A.
    Velayos, Fernando
    PRACTICAL GASTROENTEROLOGY, 2019, 43 (04) : 84 - 91
  • [32] Surgical treatment of inflammatory bowel disease
    Strong, SA
    Fazio, VW
    CURRENT OPINION IN GASTROENTEROLOGY, 1999, 15 (04) : 326 - 330
  • [33] The treatment of inflammatory bowel disease in children
    Wyllie, R
    Sarigol, S
    CLINICAL PEDIATRICS, 1998, 37 (07) : 421 - 425
  • [34] Pharmacologic treatment for inflammatory bowel disease
    Lee, Kwang Jae
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2015, 58 (01): : 57 - 63
  • [35] Rifaximin in the treatment of inflammatory bowel disease
    Guslandi, Mario
    WORLD JOURNAL OF GASTROENTEROLOGY, 2011, 17 (42) : 4643 - 4646
  • [36] Medical Treatment of Inflammatory Bowel Disease
    Park, Jong-Beom
    Kim, Hyo-Jong
    JOURNAL OF THE KOREAN MEDICAL ASSOCIATION, 2006, 49 (12): : 1164 - 1174
  • [37] Treatment of inflammatory bowel disease in the elderly
    Roque Ramos, L.
    Barosa, R.
    Mocanu, I.
    Patita, M.
    Nunes, G.
    Vieira, A. I.
    JOURNAL OF CROHNS & COLITIS, 2017, 11 : S265 - S265
  • [38] Treatment of inflammatory bowel disease with corticosteroids
    Katz, JA
    GASTROENTEROLOGY CLINICS OF NORTH AMERICA, 2004, 33 (02) : 171 - +
  • [39] Budesonide treatment for inflammatory bowel disease
    Scholmerich, J
    INFLAMMATORY BOWEL DISEASES AND CHRONIC RECURRENT ABDOMINAL PAIN, 1997, 91 : 137 - 149
  • [40] Treatment of anaemia in inflammatory bowel disease
    Koutroubakis, IE
    Karmiris, K
    Kouroumalis, EA
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2006, 23 (08) : 1273 - 1274